Precision Biosciences is a life sciences company. Co. utilizes ARCUS in the development of its product candidates, which are designed to treat human diseases and create food and agricultural solutions. Co. is developing product candidates in three areas: allogeneic chimeric antigen receptor T (CAR T) cell immunotherapy, in vivo gene correction, and food. Co.'s primary program, PBCAR0191, is an allogeneic CAR T cell therapy candidate targeting the tumor target CD19 and is being developed for the treatment of adult patients with non-Hodgkin lymphoma and relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The DTIL stock yearly return is shown above.
The yearly return on the DTIL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DTIL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|